LNC Platform Discovery
Oncology & Inflammation
DiscoveryActive
Key Facts
About Matinas Biopharma
Matinas BioPharma's mission is to overcome critical drug delivery challenges through its Lipid Nano-Crystal (LNC) platform, which facilitates oral, intracellular delivery of complex therapeutics. Its primary achievement is the advancement of MAT2203, an oral formulation of the potent but toxic antifungal amphotericin B, into Phase 2/3 clinical development with multiple FDA designations. The company's strategy involves advancing its internal pipeline in infectious disease and inflammation while seeking partnerships to leverage its LNC platform across broader therapeutic areas, including oncology and oligonucleotide delivery.
View full company profileTherapeutic Areas
Other Oncology & Inflammation Drugs
| Drug | Company | Phase |
|---|---|---|
| RNA Platform (Malat-1, LIN28) | Qubit Pharmaceuticals | Discovery |